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AbstrAct
FoxP3+ regulatory T (Treg) cells have diverse functions in the suppression of 
antitumor immunity. We show that FoxP3hiCD45RA−CD4+ Treg cells [activated Treg 
(aTreg) cells] are the predominant cell population among tumor-infiltrating FoxP3+ 
T cells, and that high aTreg cell-infiltrating content is associated with reduced survival 
in patients with head and neck squamous cell carcinoma (HNSCC). In vitro studies 
have demonstrated that aTreg cells can suppress tumor-associated antigen (TAA) 
effector T cell immune responses in HNSCC. Moreover, C-C chemokine receptor 4 
(CCR4) was specifically expressed by aTreg cells in the peripheral blood of HNSCC 
patients. Using a RayBiotech human chemokine antibody array, we showed that 
monocyte chemoattractant protein-1 (MCP-1), an endogenous CCR4-binding ligand, 
was specifically upregulated in the HNSCC microenvironment compared to the other 
four CCR4-binding ligands. Blocking MCP-1/CCR4 signaling-induced aTreg cell 
recruitment using a CCR4 antagonist evoked antitumor immunity in mice, and lead 
to inhibition of tumor growth and prolonged survival. Therefore, blocking aTreg cell 
trafficking in tumors using CCR4-binding agents may be an effective immunotherapy 
for HNSCC.
INtrODUctION
Head and neck squamous cell cancer (HNSCC) is 
the sixth most common type of cancer [1]. Despite new 
treatment modalities that can improve overall quality 
of life, survival rates have not improved in the past 
30 years [2]. Progression and recurrence of HNSCC and 
other malignancies are associated with severe immune 
dysfunction [3, 4]. Tumor-infiltrating FoxP3+CD25+CD4+ 
regulatory T (Treg) cells can promote local tumor growth 
through exerting immunosuppressive activities against 
tumor-associated antigen (TAA) T cell responses [3, 5–11]. 
Thus, tumor-infiltrating Treg cells are a major obstacle in 
cancer immunotherapy [9, 10, 12–14].
Studies involving depletion of Tregs have shown that 
depletion of CD25+ T cells enhances antitumor immune 
responses [15, 16]. However, similar studies have failed to 
demonstrate these effects [17–19]. The apparent confusion 
regarding the role of Treg cells in suppressing antitumor 
immune responses might be explained as follows. 
Activated, nonsuppressive CD4+ T cells also express 
CD25, and interleukin (IL)-2 produced by these cells is 
required for CD8+ cytotoxic T cell expansion. Depletion 
of CD25+ T cells may also reduce the number of activated 
CD4+ T cells [17]. Additionally, in some animal studies, 
total depletion of Treg cells has triggered autoimmunity 
[20–22]. Thus, we aimed to block Treg cell trafficking and 
accumulation in the tumor microenvironment, which could 
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provide an attractive therapeutic strategy against immune 
suppression.
The Sakaguchi group demonstrated that human 
FoxP3+CD25+CD4+ T cells can be divided into the following 
three functionally distinct subsets on the basis of CD45RA, 
Foxp3, and CD25 expression: (i) FoxP3loCD45RA+CD4+ 
resting Treg (rTreg) cells, which are CD25++, (ii) 
FoxP3hiCD45RA–CD4+ activated Treg (aTreg) cells, which 
are CD25+++, and (iii) cytokine-secreting FoxP3loCD45RA–
CD4+ non-Treg (nTreg) cells, which are CD25++ [23]. 
We recently reported an increase in aTreg cells, which 
are highly suppressive, and a decrease in rTreg cells in 
HNSCC patients. Although there was also an increase in 
nTreg cells, these cells did not have immune-suppressive 
activities [24, 25]. Thus, we postulated that preventing the 
accumulation of aTreg cells within a tumor could evoke and 
enhance antitumor immune responses.
Preventing the accumulation of circulating aTreg 
cells in a tumor site requires an understanding of the 
mechanisms that mediate the recruitment of these cells 
within HNSCC tissues. Chemokine receptors are one class 
of proteins that could direct Treg cell migration to tumor 
sites by sensing a specific chemokine milieu [26].
In this study, we evaluated the clinical importance 
of tumor-infiltrating aTreg cells in HNSCC patients. We 
found that the C-C chemokine receptor (CCR) 4 was 
predominantly expressed on aTreg cells compared to rTreg 
and nTreg cells, FoxP3–CD4+ T cell subsets, and other types 
of immune cells, indicating that CCR4-binding agents 
could be used to selectively block aTreg cell trafficking. 
Additionally, we showed that MCP-1/CCR4 signaling 
induced aTreg cell trafficking in tumors. Blockade of aTreg 
cell trafficking augmented the antitumor immune response 
thereby preventing xenograft tumor growth and prolonging 
mouse survival.
rEsULts
Accumulation of atreg cells in HNscc tissue 
accelerates disease progression and predicts poor 
survival
We first analyzed the prevalence of tumor-infiltrating 
FoxP3hiCD45RA−CD4+ aTreg cells in 19 clinical HNSCC 
specimens. The majority of tumor-infiltrating FoxP3+ 
T cells were FoxP3hiCD45RA−CD4+ aTreg cells (Fr. II) 
(Figure 1A). Moreover, the frequency of these aTreg cells 
in tumors was significantly higher than in PBMCs and 
adjacent nontumor tissues (P < 0.001) (Figure 1B–1D).
Because the various subtypes of HNSCC have 
different etiologies and survival rates, we examined 72 
patients with laryngeal squamous cell cancer (LSCC), the 
most common type of HNSCC, in this study (Table 1). 
Double immunohistochemical staining revealed 
substantial infiltration of aTreg cells in the peritumoral 
area and stroma of tumors (Figure 1E). All tumor-
infiltrating FoxP3+ cells were CD25+ T cells, while 93.6 
± 8.8% of CD25+ T cells were FoxP3+ cells in the tumor 
tissue. The median level of aTreg cell infiltration was 
3.75 (range: 0–24) in the whole population. When the 
median value was used as a cutoff to define low and 
high levels of aTreg cell infiltration, the percentage 
of tumor differentiation was indicated (Figure 1F). 
We did not find a correlation between the infiltration level 
of aTreg cells and pathological stage (Figure 1G). However, 
the level of aTreg cell infiltration in patients at early clinical 
stages (I and II) was lower than that at late clinical stages 
(III and IV) (P < 0.001) (Figure 1H, 1I) (Supplementary 
Table 1).
We hypothesized that tumor-infiltrating aTreg cells 
would adversely correlate with survival. In univariate 
analysis, the low level group was associated with a longer 
survival time (p = 0.001) (Figure 1J). Survival was still 
significantly different for the group at stages III and IV 
(p = 0.036; median: 9.75) (Figure 1K), but not stages I 
and II (P = 0.49; median: 2.50) (Figure 1L). Therefore, 
an increase in the number of tumor-infiltrating aTreg cells 
was a significant predictor of reduced survival in patients 
with LSCC.
In a Cox multivariate analysis, only two variables 
influenced the overall survival probability: clinical stage 
(p = 0.04; relative risk: 1.65) and the level of infiltration of 
aTreg cells (p = 0.035; relative risk: 4.05; Supplementary 
Table 2). Differences in treatment modalities and other 
factors known to correlate with survival were included in 
this model and did not change the significance of these 
variables.
atreg cells suppress tAA immunity in vitro
To evaluate the suppressive functions of aTreg cells 
in TAA immunity, immature DCs were loaded with soluble 
antigens from a cancer cell lysate (SNU899 laryngeal 
cancer cell line), and then co-cultured with autologous 
lymphocytes, which induced specific T cell activation 
as expected (Supplementary Figure 1). This induction of 
TAA CD4+ and CD8+ T cell proliferation was markedly 
inhibited by allogeneic aTreg cells that were prepared as 
described previously [24, 25] (Figure 2A–2C). Moreover, 
the frequencies of interferon (IFN)-γ+, IL-2+ and tumor 
necrosis factor (TNF)-α+CD4+ T cells were reduced by 
aTreg cells (Figure 2D–2F). The Th1 subset (IFN-γ+IL-2+ 
and IFN-γ+TNF-α+) decreased by more than 50% when 
aTreg cells were added to the co-culture system (Figure 
2G, 2H). We quantified the number of cytokine-secreting 
cells per well in 96-well plates and determined that the 
numbers of IFN-γ+, IL-2+, TNF-α+, IFN-γ+IL-2+, and IFN-
γ+TNF-α+ cells were significantly reduced in the presence 
of aTreg cells (Figure 2I, P < 0.01 for all).
Finally, the cytotoxicity of antigen-loaded 
autologous immature DCs was assessed because the major 
histocompatibility complex (MHC) could be matched to 
reactive cytotoxic T lymphocytes [27]. The addition of aTreg 
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Figure 1: Phenotype and clinical implications of tumor-infiltrating Treg cells. (A–D) Predominant infiltration of aTreg cells 
into HNSCC tissues. (A) CD4+ T cells from peripheral blood, adjacent nontumor sites, and tumor sites were fractionated into subpopulations 
based on the expression of CD45RA and FoxP3. The frequency of CD4+ T cells in each fraction was analyzed. Data from two representative 
patients are shown. (B–D) Comparison of the frequency of aTreg cells within peripheral blood, adjacent nontumor sites, and tumor sites 
(n = 19). (E) Immunohistochemistry of aTreg cells in LSCC samples (n = 72). Representative images showing staining of aTreg cells within 
the tumor, stroma, and peritumor sites are shown. Brown: FoxP3; Red: CD25. Scale bars: 30 μm. The lower panels are magnified images of 
the boxed area in the corresponding upper panel. (F) Comparison of the percentage of differentiation of tumors with low levels of aTreg cell 
infiltration compared to those with high levels. (G) Box plot showing quantitative evaluation of aTreg cell infiltration. Statistical differences 
between the three groups were analyzed using Kruskal-Wallis tests. (H–I) The level of aTreg cell infiltration in patients with early-stage 
tumors was lower than the level in patients with late-stage tumors. (H) Representative images showing staining of aTreg cells within tumor 
tissues from patients with early-stage (I and II) and late-stage (III and IV) tumors. (I) Statistical differences between the two groups were 
analyzed using Mann-Whitney U-tests. (J–L) Accumulation of tumor-infiltrating aTreg cells predicts poor survival in patients with LSCC. 
Kaplan-Meier curve for overall survival according to the number of tumor-infiltrating aTreg cells in 72 LSCC patients at (J) stages I–IV, 
(K) stages III and IV only, or (L) stages I and II only. Samples were divided into two groups based on the level of aTreg cell infiltration.
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cells resulted in a decrease in the average percentage of 
cytotoxicity from 42.3% to 12.5% (Figure 2J, 2K, P < 0.05), 
indicating that aTreg cells blocked the protective effects of 
T cells in the tumor. These data indicated that aTreg cells 
suppressed TAA effector T cell immunity in patients with 
HNSCC.
ccr4 is predominantly expressed on atreg cells
To identify proteins involved in the recruitment of 
circulating aTreg cell to HNSCC tumors, we compared 
the expression of CCR4, CCR5, CCR6, CCR7, and 
C-X-C chemokine receptor (CXCR) 4 [3, 7, 26] in 
circulating FoxP3+CD25+CD4+ Treg cells from HNSCC 
patients (Supplementary Figure 2). We then focused 
on the expression of these chemokine receptors on 
FoxP3+CD25+CD4+ T cell subsets and FoxP3−CD4+ T 
cells. The results showed that chemokine receptor-positive 
T cells were present in both the FoxP3+ and FoxP3− T 
cell fractions (Figure 3A). When FoxP3+ T cells were 
classified into three subsets according to FoxP3 and 
CD45RA expression [24, 25], only FoxP3hiCD45RA− 
aTreg cells (Fr. II) predominantly expressed CCR4; 
FoxP3loCD45RA+ rTreg cells (Fr. I) exhibited low CCR4 
expression and FoxP3loCD45RA− non-Treg cells (Fr. III) 
exhibited moderate expression. Among the FoxP3− cells, 
some CD45RA−CD4+ memory and activated T cells (Fr. 
IV) expressed CCR4, while CD45RA+CD4+ naive T cells 
(Fr. V) did not (Figure 3B). Analysis of the expression of 
four other chemokine receptors (CCR5, CCR6, CCR7, and 
CXCR4) revealed that the expression of these chemokine 
receptors on the above CD4+ T cell fractions did not show 
the same pattern as CCR4. Specifically, aTreg cells (Fr. II) 
and the four other fractions (Fr. I, III, IV, and V) exhibited 
low CCR5 and CCR6 expression (Figure 3B). Although 
high expression of CCR7 and CXCR4 was observed 
in aTreg cells, the other four fractions exhibited high 
expression (Figure 3B), indicating that CCR7 and CXCR4 
could not be used for selective blockade of aTreg cell 
trafficking in tumors. Mean fluorescence intensity (MFI) and 
frequency analysis of multiple samples of peripheral blood 
mononuclear cells (PBMCs) from HNSCC patients showed 
similar patterns of chemokine receptor expression in FoxP3+ 
subsets (Figure 3C, 3D). Moreover, PBMCs from healthy 
individuals showed similar patterns of CCR4 expression in 
FoxP3+ subsets (Supplementary Figure 3).
To confirm that CCR4 blockade could be used to 
selectively prevent circulating aTreg cell trafficking, we 
analyzed the expression of CCR4 on various types of 
immune cells. The results indicated that CD8+ T cells, 
activated CD4+ T cells, natural killer (NK) cells, CD14+ 
monocytes/macrophages, dendritic cells (DCs), and B 
cells did not significantly express CCR4 (Supplementary 
Figure 4). Finally, we compared the expression of CCR4 
on HNSCC tumor-infiltrating aTreg cells and matched 
circulating aTreg cells from 18 HNSCC patients. These 
results demonstrated that tumor-infiltrating aTreg cells 
predominantly expressed CCR4, which was consistent 
table 1: clinicopathological features of Lscc patients
No. cases %
Gender Male 68 94.40
Female 4 5.60
Age (year) < 61 35 48.61
≥ 61 37 51.39
Tumor grade G1 34 47.22
G2 27 37.50
G3 11 15.28
Tumor status T1–2 42 58.33
T3–4 30 41.67
Nodal status N0 58 80.56
N1–2 14 19.44
Stage (UICC 2008) I–II 38 52.78
III–IV 34 47.22
M stage M0 72 100.00
M1 0 0.00
LSCC: Laryngeal squamous cell carcinoma.
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with the expression pattern in circulating aTreg cells 
(Supplementary Figure 5). Thus, inhibition of CCR4 
blocked aTreg cell trafficking in HNSCC.
McP-1 is highly expressed in the HNscc 
microenvironment
CCR4 is a receptor for monocyte chemoattractant 
protein-1 (MCP-1), regulated on activation, normal T 
cell expressed and secreted (RANTES), macrophage 
inflammatory protein-1a (MIP-1a), thymus and activation 
regulated chemokine (TARC), and macrophage-derived 
chemokine (MDC). We investigated whether the expression 
one of these endogenous CCR4-binding ligands was 
specifically increased in the HNSCC microenvironment. We 
used antibody arrays (RayBiotech) to screen the levels of 
38 chemoattractant factors (Figure 4A, 4B) in paired tumor 
and adjacent nontumor tissues from four HNSCC patients. 
Approximately 23 secreted factors were detected in both 
tumor tissues and adjacent nontumor tissues (Figure 4C). 
Interestingly, among the five chemoattractant ligands 
for CCR4, only MCP-1 was increased in tumor tissues 
compared with adjacent nontumor tissues, while RANTES, 
MIP-1a, TARC, and MDC were not. The expression of 
CCR5, CCR6, CCR7, and CXCR4 ligands was low or 
undetectable (Figure 4D). To confirm endogenous MCP-1 
Figure 2: atreg cells inhibit tAA immunity in vitro. (A–c) Inhibition of TAA T cell proliferation by aTreg cells. Antigen-loaded 
mature DCs (TAA-mDCs) were added to autologous T cells in the presence of aTreg cells. Six days after the second stimulation, (A) CD4+ 
and (B) CD8+ T cell proliferation were assessed by flow cytometry. (C) Statistical comparisons were performed using Student’s t-tests. 
(D–I) Inhibition of TAA CD4+ T cell production of IFN-γ, IL-2, and TNF-α by aTreg cells. T cells were stimulated with TAA-mDCs, 
and Th1 cytokines detected by intracellular staining. Secretion of (D) IFN-γ, E. IL-2, and (F) TNF-α, and the frequencies of Th1 subsets 
((G) IFN-γ+IL-2+ and (H) IFN-γ+ TNF-α+) were significantly inhibited by aTreg cells. (I) Statistical comparisons were performed using 
Student’s t-tests. (J–K) Inhibition of TAA T cell cytotoxicity by aTreg cells. (J) The cytotoxicity of TAA-immature DCs was analyzed by 
flow cytometry with annexin V and 7-AAD staining. (K) Experiments were performed in triplicate and repeated twice. A representative 
experiment is shown. Statistical comparisons were performed using Student’s t-tests. *P < 0.05 and **P < 0.01.
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Figure 3: CCR4 is predominantly expressed on aTreg cells in HNSCC patients. (A) CCR4, CCR5, CCR6, CCR7, and 
CXCR4 expression by subpopulation of FoxP3+ Treg cells in PBMCs from HNSCC patients. (b) The expression of CCR4, CCR5, CCR6, 
CCR7, and CXCR4 was evaluated in each fraction of CD4+ T cells. Representative data from 50 HNSCC patients are shown. (c) Mean 
fluorescence intensity (MFI, upper) and frequency (lower) of CCR4, CCR5, CCR6, CCR7, and CXCR4 expression by each fraction of 
CD4+ T cells in PBMCs from HNSCC patients (n = 50). Statistical differences were analyzed using Kruskal-Wallis tests. *P < 0.05, 
**P < 0.001, and ***P < 0.0001. (D) Summary of MFIs (mean, upper) and frequency (mean, lower) of CCR4, CCR5, CCR6, CCR7, and 
CXCR4 in each fraction of CD4+ T cells. I: FoxP3loCD45RA+CD4+ resting Treg cells; II: FoxP3hiCD45RA–CD4+ aTreg cells; III: cytokine-
secreting FoxP3loCD45RA–CD4+ non-Treg cells; IV: FoxP3–CD45RA–CD4+ T cells; V: FoxP3–CD45RA+CD4+ T cells.
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expression within the HNSCC microenvironment, 
tissue sections from 15 HNSCC biopsies were stained 
using antibodies specific for MCP-1 and two unique 
chemoattractant ligands (MDC and TARC) for CCR4 
(Figure 4E). The immunohistochemistry data were 
consistent with that of the antibody array. Therefore, we 
postulated that HNSCC-circulating aTreg cells could be 
recruited to the tumor microenvironment by endogenous 
MCP-1 through binding to CCR4.
McP-1/ccr4 signaling increases circulating 
aTreg cell trafficking in tumors
MCP-1 is a chemoattractant ligand for both CCR4 
and CCR2. Therefore, we could not conclude that CCR4 
was the only functional receptor in MCP-1-induced 
circulating aTreg cell recruitment. To elucidate the specific 
chemoattractant responsible for aTreg cell recruitment, we 
first analyzed CCR2 expression on circulating aTreg cells 
from both HNSCC patients and healthy donors. CCR2+ T 
cells were nearly absent in FoxP3+CD4+ T cell fractions, 
indicating that HNSCC-circulating aTreg cells may be 
recruited to the tumor microenvironment by endogenous 
MCP-1 via binding to CCR4 but not CCR2 (Figure 5A, 5B).
We next examined whether the CCR4 on aTreg cells 
was functional. Freshly isolated circulating aTreg cells 
from HNSCC patients were analyzed in migration assays 
(n = 3). The data showed that freshly isolated tumor 
extracts induced significant migration of aTreg cells 
in vitro (P < 0.01 versus control [media]). In addition, 
both a monoclonal antibody against human MCP-1 and 
a CCR4 antagonist significantly blocked tumor extract-
induced aTreg cell migration (P < 0.01 for each). In 
support of these results, recombinant MCP-1 induced 
significant aTreg cell migration (P < 0.01 versus control) 
that was efficiently blocked by the anti-MCP-1 antibody 
and CCR4 antagonist (P < 0.01 for each) (Figure 5C). 
Thus, MCP-1 could increase aTreg cell trafficking via 
binding to CCR4 in vitro and could recruit aTreg cells 
to tumors.
Figure 4: MCP-1 is increased in tumor tissues from HNSCC patients. (A) Map of antibodies against chemokines on the 
RayBiotech Human Chemokine Antibody Array (AAH-CHE-G1). (b) Cell lysates from tumor and adjacent nontumor tissues were first 
applied to the array. Bound chemokines were then recognized by a pool of anti-chemokine antibodies corresponding to the antibodies 
spotted on the array. Similar results were observed in two independent arrays. (c) Semiquantification of scanned antibody arrays. The 
levels were normalized to internal positive controls present in each membrane. Semiquantitative levels are represented in the heat map. 
(D) Expression of CCR4, CCR5, CCR6, CCR7, CXCR4 ligands in tumor and adjacent nontumor tissues. Statistical differences were 
analyzed using Mann-Whitney U-tests. (E) Representative staining of HNSCC cases for MDC, TARC, and MCP-1 (n = 15). Brown: 
positive staining × 100. Lower panels are magnified images of the boxed area in the corresponding upper panel. NT: nontumor; T: tumor.
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Figure 5: MCP-1/CCR4 signaling promotes aTreg cell migration. (A), (b) CCR2-positive T cells were scarcely present in 
fractions of FoxP3+CD4+ and FoxP3-CD4+ T cells. (A) CCR2 expression by subpopulation of FoxP3+ Treg cells in PBMCs from HNSCC 
patients and healthy donors. (B) Expression of CCR2 in CD4+ T cell fractions. Representative data from 19 HNSCC patients and 12 healthy 
donors are shown. (c) Migration of aTreg cells in response to a tumor extract or recombinant MCP-1. A specific anti-MCP-1 antibody or 
CCR4 antagonist significantly inhibited aTreg cell migration. Results are the mean ± SD. Statistical differences were analyzed by one-way 
analysis of variance (ANOVA). *P < 0.01.
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A CCR4 antagonist evokes and enhances 
antitumor immune responses in vivo
We next determined whether CCR4-binding treatment 
could evoke and enhance antitumor immunity in vivo (n = 6 
per group, C3H-HeN mice). After administration of a CCR4 
antagonist, we observed inhibition of SCC-VII tumor growth 
at day 33 (P < 0.01 for each, Figure 6A) and prolongation 
of the overall survival time (P < 0.05 for each, Figure 6B) in 
the CCR4 antagonist-treated group compared to the control 
groups. One mouse in the CCR4 antagonist-treated group 
was still alive at the end of the observation period at day 
50. The frequency of tumor-infiltrating aTreg cells was also 
lower in the CCR4 antagonist-treated group than in the PBS/
blank control groups (P < 0.05 for each), suggesting that 
the CCR4 antagonist inhibited aTreg cell migration in vivo 
(Figure 6C). The frequency of tumor-infiltrating CD4+ T 
cells was higher in the CCR4 antagonist-treated group than 
in the control groups, but the difference was not statistically 
significant. The frequency of tumor-infiltrating CD8+ T 
cells in the CCR4 antagonist-treated group was higher than 
in the control groups (P < 0.05 for each, Figure 6D). We 
next examined the cytokine profiles of tumor-infiltrating 
lymphocytes following ex vivo stimulation, and found 
that T cells in the CCR4 antagonist-treated group secreted 
significantly higher amounts of IFN-γ, IL-2, and TNF-α than 
T cells in the control groups (P < 0.05 for each) (Figure 6E).
DIscUssION
Accumulating evidence indicates that FoxP3+ 
Treg cells can suppress tumor-specific immunity, 
which provides a clear rationale for development of 
immunotherapies that can modulate the influence of 
these regulatory cells [3, 17, 28]. Here, we investigated 
the distribution of FoxP3+ T cell subsets in HNSCC 
tissues. Intriguingly, our data showed that the majority 
of tumor-infiltrating FoxP3+ T cells were aTreg cells. 
Although there is a large amount of evidence that FoxP3+ 
T cells predominantly infiltrate tumor tissues [6, 7, 17, 
29, 30], the detailed phenotypes of these FoxP3+ T cells 
have not been characterized. Our finding of predominant 
aTreg cell infiltration revealed the phenotypes of such 
cells. Additionally, aTreg cell numbers were significantly 
higher in late-stage (III and IV) HNSCC tumor tissue 
than in early-stage tissue (I and II), and were inversely 
Figure 6: A CCR4 antagonist blocks aTreg cell trafficking in tumors leading to enhanced antitumor immune responses 
and prolonged survival. (A) Tumor sizes were measured every 3 days after tumor cell injection (left panel). Tumors isolated 33 days 
after injection are shown in the right panel. Data are presented as the mean ± SD. P < 0.05 for the PBS or blank control groups versus the 
CCR4 antagonist-treated group. (b) Survival depicted as the percentage of surviving mice on the indicated day after tumor cell injection. 
Statistical comparisons were performed using the Kaplan-Meier test. P < 0.05 for the PBS or blank control groups versus the CCR4 
antagonist-treated group. Frequencies of (c) aTreg cells, (D) CD4+, CD8+ T cells, and E. CD4+ T cells that secreted IFN-γ, IL-2, and TNF-α. 
Histograms show the frequencies of each T cell subset. Statistical comparisons were performed using one-way ANOVA. *P < 0.05 and 
**P < 0.01.
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correlated with patient prognosis. Given the clinical 
importance of tumor-infiltrating aTreg cells, inhibition 
of aTreg cell recruitment in HNSCC may be an effective 
immunotherapeutic strategy.
We recently confirmed that aTreg cells suppress 
proliferation of non-TAA T cells [24, 25]. However, there 
has been no definitive demonstration of the role of aTreg 
cells in TAA immunity. Our data showed that aTreg cells 
from HNSCC patients inhibit TAA immunity, which 
resulted in lower TAA-loaded cell cytotoxicity in vitro. 
These findings provide a rationale for the development of 
immunotherapies to control the effects of aTreg cells in 
HNSCC.
Since chemokine receptors have central roles in the 
recruitment of immunoregulatory cells [7, 17, 31, 32, 33], 
we focused on the expression of these receptors in aTreg 
cells in order to identify a specific chemokine receptor that 
could be inhibited to block aTreg cell trafficking. The data 
indicated that aTreg cells predominantly expressed CCR4 
compared with FoxP3+/−CD4+ T cell subsets and other types 
of immune cells. This result was consistent with a previous 
study, which showed that CCR4 was predominantly 
expressed in peripheral blood aTreg cells from melanoma 
patients [34]. These data strongly suggest that blockade of 
aTreg cells by therapeutics that bind CCR4 may be used to 
selectively prevent circulating aTreg cell trafficking.
Circulating FoxP3+ Treg cells express CCR4 and 
migrate in response to TARC and MDC [35–38]. However, 
it is unknown whether these chemoattractants are involved 
in aTreg cell homing to HNSCC tumors. Here, we showed 
that TARC and MDC were not significantly expressed in 
HNSCC tissues. In contrast, MCP-1, a chemoattractant 
ligand for both CCR2 and CCR4, was highly expressed in 
HNSCC tissues compared to adjacent nontumor tissues. 
This finding indicated that MCP-1, but not TARC or 
MDC, was involved in aTreg cell trafficking in tumors 
via CCR2 and/or CCR4. CCR2 is expressed on blood 
lymphocytes such as monocytes, NK cells, and B cells 
[39–41]. However, whether aTreg cells expressed CCR2 
was unclear. We observed low expression of CCR2 on 
aTreg cells. In addition, we determined that circulating 
aTreg cells, which highly express functional CCR4, 
migrated toward MCP-1 in the tumor microenvironment.
Our in vivo studies showed that inhibition of 
tumor growth and prolonged mouse survival could be 
attributed to inhibition of aTreg cell recruitment resulting 
in expansion of tumor infiltrating CD4+ and CD8+ T cells. 
These data demonstrate that aTreg cells are involved in 
the progression of HNSCC via their suppressive effects 
on TAA immune responses. Therefore, therapeutics that 
bind aTreg cells could be an effective immunotherapy for 
HNSCC. Several recent clinical trials have shown that 
depletion of CCR4-expressing FoxP3+CD4+ Treg cells by 
anti-human CCR4 monoclonal antibody is a promising 
approach to augment antitumor immune responses in 
cancer patients [42, 43]. The above findings give us 
confidence that inhibiting CCR4-expressing aTreg cell 
recruitment may be an effective strategy in HNSCC 
immunotherapy.
In conclusion, our data suggest that a combination 
of a CCR4-binding therapeutic that can block aTreg cell 
trafficking in tumors, tumor antigen immunization, and 
monoclonal antibodies may enhance the clinical efficacy 
of immunotherapies for HNSCC.
MAtErIALs AND MEtHODs
Donor samples
PBMCs were obtained from healthy donors and 
HNSCC patients who had not received any previous 
oncological treatments. Tumor- and nontumor-infiltrating 
lymphocytes were obtained from tumor and adjacent 
nontumor tissues after surgical debulking. Informed consent 
was obtained from all participants prior to enrollment in the 
study. The study was approved by the Ethics Committee 
of The First Affiliated Hospital of Sun Yat-sen University, 
Guangzhou, China (Approval No. 2012-349).
Preparation of infiltrating lymphocytes
Infiltrating lymphocyte suspensions were prepared 
by enzymatic digestion [44]. Dissected tumor or adjacent 
nontumor tissues were minced into small pieces with a 
scalpel. Samples (0.25 g) were then immersed in 10 mL 
of a digestion mixture [RPMI 1640 containing 5% fetal 
bovine serum, 0.5 mg/mL collagenase A, 0.2 mg/mL 
hyaluronidase type V, and 0.02 mg/mL DNase I (Sigma-
Aldrich St. Louis, MO, USA)]. The samples were incubated 
on a rotating platform at 37°C for 30 min and the resulting 
cell suspensions filtered through 40-mm cell strainers (BD 
Biosciences, San Diego, CA, USA). Finally, lymphocyte 
suspensions were obtained using Ficoll-Hypaque (Haoyang 
Bio, Tianjing, China).
cell lines and mice
The SNU899 LSCC cell line was provided by 
Professor Ja-Lok Ku (Seoul National University College of 
Medicine, South Korea). The mouse SCC VII OSCC cell line 
was provided by Professor Si-Xi Liu (West China Hospital, 
China). Cells were cultured under standard conditions.
Eight-week old male C3H-HeN mice were purchased 
from Slac Laboratory Animal Co., Ltd. (Shanghai, China). 
All mice were housed under specific pathogen-free 
conditions. Experimental procedures were approved by 
the Institutional Animal Studies Committee and conducted 
in accordance with Institutional Animal Care and Use 
Committee guidelines.
Preparation of Dcs and tAA loading
 CD14+ cells were isolated from PBMCs using 
CD14 Microbeads (Miltenyi Biotec, Bergisch Gladbach, 
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Germany). The cells were then seeded into a 6-well plate at 
a density of 1.5 × 106 cells/well and cultured as described 
previously [45]. On day 6, soluble SNU899 lysate antigens 
prepared by four freeze-thaw cycles (−140°C/42°C/60°C) 
were added to DC cultures at a ratio of 3:1 (SNU899 cells: 
DCs). On day 7, maturation of DCs was induced by the 
addition of 1 μg/mL lipopolysaccharide (Sigma-Aldrich) 
and the cells cultured for an additional 2 days. On day 9, 
DC phenotype was evaluated by flow cytometry (Gallios 
Flow Cytometer, Beckman Coulter, Hercules, CA, USA) 
using anti-hCD1a-PE-Cy7, anti-hCD83-FITC, anti-hHLA-
DR-eFluor 450, anti-hCD80-PE-Cy5, anti-hCD86-PE, and 
anti-hCD40-APC (eBioscience, San Diego, CA, USA) 
antibodies.
Intracellular cytokine secretion assay
 After stimulation for 5 h with a cocktail of phorbol 
12-myristate 13-acetate, ionomycin, and Golgi stop 
(brefeldin A and monensin) (eBioscience), cells were 
stained for cell surface markers and intracellular cytokines 
(IL-2, TNF-α, and IFN-γ) using anti-hTNF-α-Alexa Fluor 
700, anti-hIL-2-PE-Cy7, and anti-hIFN-γ-APC-eFluor 780 
antibodies as well as the Fixation/Permeabilization Buffer 
and Permeabilization Buffer from eBioscience.
In vitro tAA immunosuppression in the presence 
of atreg cells
Antigen-loaded DCs were added to autologous T 
cells as stimulators at a ratio of 1:20 in a round bottom 
96-well microplate. The aTreg cells were prepared as 
described previously [24, 25] and added to cultures 
of antigen-loaded DCs and T cells at a ratio of 1:4. A 
second identical stimulation by antigen-loaded DCs was 
performed after 1 week. On day 13, CD4+ and CD8+ T 
cell proliferation and cytokine production of CD4+ T cells 
were assessed by flow cytometry using anti-hCD3-eFluor 
450, anti-hCD4-FITC, anti-hCD8a-PE-Cy7, anti-hIFN-
γ-APC-eFluor780, anti-hIL-2-PE-Cy7, and anti-hTNF-
α-Alexa Fluor 700 antibodies (eBioscience). SNU899-
derived, lysate-pulsed immature DCs were labeled with 
5 µM 5,6-carboxyfluorescein diacetate succinimidyl ester 
(eBioscience) and mixed with T cells that had been cultured 
for 13 days at a ratio of 1:10 in 96-well microplates for 4 h 
in a 5% CO2 atmosphere at 37°C. Cytotoxicity was assessed 
by flow cytometry using APC-annexin V and 7-amino-
actinomycin D (7-AAD) (BD Biosciences).
Identification of FoxP3+cD4+ t cell subsets
 To identify FoxP3+CD4+ T cell subsets, T cells 
obtained from tumor tissues, adjacent non-tumor tissues, 
and blood were stained with anti-hCD3-eFluor 605NC, 
anti-hCD4-FITC, anti-hCD25-APC, anti-hCD45RA-
eFluor 450, and anti-hFoxP3-PE antibodies (eBioscience).
Immunohistochemical analysis
The main clinical and pathological characteristics of 
LSCC patients are presented in Supplementary Table 4. 
Clinical staging and the anatomical site of the tumors 
were assessed according to the 6th edition of the Union for 
International Cancer Control (UICC 2008) tumor-node-
metastasis classification of malignant tumors. Detection of 
FoxP3 (Ab22510, IgG1, 1:50 dilution, Abcam, Cambridge, 
MA, USA) and CD25 (Ab61777, IgG, 1:100 dilution, 
Abcam) was performed on 4 μm-thick, paraffin-embedded 
sections of tissue samples with the indicated antibodies 
using a double staining kit (DS-0001, ZSGB-BIO, Beijing, 
China). For chemokine receptor ligand staining, sections 
of tissue samples were stained with anti-MCP-1, -MDC, 
or -TARC antibodies using an ABC kit (PK-4001, ZSGB-
BIO).
Chemokine receptor expression profiling
 The expression of CCR2, CCR4, CCR5, CCR6, 
CCR7, and CXCR4 on lymphocytes was analyzed by flow 
cytometry using anti-hCD3-eFluor 605NC or anti-hCD3-
eFluor 450, anti-hCD4-FITC, anti-hCD8-PE-Cy7, anti-
hCD25-APC, anti-hCD45RA-eFluor 450, anti-hFoxP3-PE, 
anti-hCD14-FITC, anti-hCD19-PE-Cy7, anti-hCD11c-
Alexa Fluor 700, anti-hCD16-PE, anti-hCD56-APC, anti-
hCCR6-PerCP-eFluor710, anti-hCCR7-APC-eFluor780, 
and anti-hCXCR4-PE-Cy7 antibodies (eBioscience). The 
anti-hCCR2-Alexa Fluor 647, anti-hCCR4-PerCP-Cy5.5, 
and anti-hCCR5-APC-Cy7 antibodies were purchased 
from BD Pharmingen (San Diego, CA, USA).
RayBiotech human chemokine antibody array
 A Human Chemokine Antibody Array (RayBiotech, 
Inc, Norcross, GA, USA) was used according to the 
manufacturer’s instructions. After development, films were 
scanned and the images processed and quantified using 
the National Institutes of Health ImageJ software. The 
intensities were normalized to internal positive controls for 
comparison.
Migration assay
 Migration was assessed as described previously [31] 
using 5 × 104 aTreg cells. Human recombinant MCP-1 
(0.5 μg/mL, R&D Systems, Minneapolis, MN, USA), a 
human anti-MCP-1 antibody (Monoclonal Mouse IgG1 
Clone #24822, 15 μg/mL, R & D Systems), or tumor 
tissue extract were added to the lower chamber. The 
aTreg cells were preincubated with a CCR4 antagonist 
(C27H41N5O2.2HCl, 0.14 μM, TOCRIS, Minneapolis, MN, 
USA) for 30 min at 37°C. Migrated cells were counted using 
an automated cell counter (Scepter, Millipore, Billerica, 
MA, USA).
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In vivo augmentation of antitumor immune 
responses by the ccr4 antagonist
Eighteen C3H-HeN mice were randomly and equally 
divided into three groups and ear tagged prior to treatment. 
On day 0, 1 × 105 tumor cells were injected subcutaneously 
into the right flank. Either a CCR4 antagonist (87.5 μg) 
or saline were injected intraperitoneally three times per 
week for 3 weeks from day 5 after tumor cell injection. In 
parallel, a group of six mice was used as a blank control. 
Tumor size was measured every 3 days using fine calipers. 
Tumor volumes were calculated as length × (width)2 × 0.52. 
All mice were sacrificed 7 days after the last injection.
After sacrifice, tumors were removed and single cell 
suspensions were prepared by enzymatic digestion. The 
types of tumor infiltrating cells were analyzed by flow 
cytometry using anti-mouse CD3-FITC, anti-mouse CD4-
eFluor 450, anti-mouse CD8-Alexa Fluor 700, anti-mouse 
CD25-APC, anti-mouse IL-2-PE, anti-mouse IFN-γ-PE-
Cy-5, anti-mouse TNF-α-PE-Cy7, anti-mouse FoxP3-PE, 
and anti-mouse CD45RA-FITC antibodies (Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA), and a fixation/
permeabilization kit. All antibodies were purchased from 
eBioscience unless otherwise specified. An additional 
three randomly divided groups of mice were used for 
survival analysis. The observation period was 50 days.
statistical analysis
 Statistical analysis was performed with SPSS 
Standard version 13.0 software (IBM, Chicago, IL, USA). 
Differences between groups were assessed using Mann-
Whitney U-tests, Student’s t-tests, or Kruskal-Wallis tests. 
Comparisons of aTreg cell infiltration levels between groups 
were performed using the Wilcoxon matched-pairs signed-
ranks test. Survival variables were estimated using the 
Kaplan-Meier method and compared using log-rank tests. 
Multivariate analysis using the Cox proportional hazard 
model was used to determine the influence of each variable, 
when adjusted to the others, on overall survival. A P-value 
of less than 0.05 was considered statistically significant.
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